not bad - they're back on track....but could be betterrefer back...

not bad - they're back on track....but could be better
refer back to my post in July, and again in March: https://hotcopper.com.au/posts/62601871/single

heres this Qtr vs last Qtr



they're under 1.4m burn per qtr due to inventory drawdown - as per plan
they also forecast next Qtr to be a repeat, under 1m burn due to inventory drawdown (we'l wait and see)


where they need to improve:
-revenue is up only 6%, forecast over 9%
-small price increase (inflation + competitor matching); Current margin 47.5%. target Gross margin of 50%. Still a bit to go. Maybe need another price increase because inflation is more than forecast
-not replace senior exec's. staff costs are up
-cutback on marketing + R&D
-Invest (spend) on the clinical study is costing more than planned.

based on this, and the economic headwinds, inflation etc i think they'l miss their target from their May Investor preso, and will need to raise more money before Dec 2023, where they plan on becoming operational CF +ve
https://hotcopper.com.au/threads/ann-investor-presentation.6754558/#post-61524559